What are Immunovant, Inc.'s total assets?

Immunovant, Inc. (IMVT) holds $957.0M in total assets, up 23.3% year over year.

How much debt does Immunovant, Inc. have?

Immunovant, Inc. carries $72.0K in total debt against $852.6M of shareholders' equity, a debt-to-equity ratio of 0.00.

How much cash does Immunovant, Inc. have?

Immunovant, Inc. holds $902.1M in cash and equivalents.

Can Immunovant, Inc. cover its short-term obligations?

Its current ratio is 9.09 — current assets exceed current liabilities.

Where does Immunovant, Inc.'s balance sheet data come from?

Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Immunovant, Inc. IMVT Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'26	FY'25	FY'24	FY'23
Cash and cash equivalents	$902.11M+26.4%	$713.97M+12.4%	$635.37M+68.7%	$376.53M-23.8%
Accounts receivable, net	$6.68M-22.3%	$8.6M-0.1%	$8.61M-53.1%	$18.36M-8.9%
Prepaid expenses and other current assets	$42.76M-16.4%	$51.18M+106%	$24.9M-7.5%	$26.92M+330%
Total current assets	$948.82M+23.6%	$767.66M+15.3%	$665.77M+64.7%	$404.33M-21.2%
Property and equipment, net	$443K-47.5%	$844K+82.7%	$462K+38.7%	$333K+0.9%
Other non-current assets	$7.68M+0.8%	$7.62M—	$0—	——
Total assets	$957.01M+23.3%	$776.22M+16.5%	$666.37M+64.2%	$405.84M-21.3%
Accounts payable	$7.54M-57.3%	$17.66M+147%	$7.16M+429%	$1.35M-92.7%
Accrued expenses	$175K-35.9%	$273K+1,720%	$15K-95.7%	$350K-98.6%
Total current liabilities	$104.42M+51.8%	$68.78M+41.5%	$48.61M+12.3%	$43.3M-2.7%
Total liabilities	$104.42M+51.8%	$68.78M+41.5%	$48.61M+12.1%	$43.34M-5.2%
Common stock	$20K+25.0%	$16K+14.3%	$14K+7.7%	$13K+8.3%
Additional paid-in capital	$2.6B+33.5%	$1.95B+35.0%	$1.44B+55.3%	$927.98M+12.5%
Retained earnings	-$1.75B-40.8%	-$1.24B-50.1%	-$825.68M-45.8%	-$566.35M-59.4%
Accumulated other comprehensive income (loss)	$730K-50.0%	$1.46M-23.5%	$1.91M+124%	$852K+111%
Total stockholders' equity	$852.59M+20.5%	$707.45M+14.5%	$617.76M+70.4%	$362.49M-22.8%
Total liabilities and stockholders' equity	$957.01M+23.3%	$776.22M+16.5%	$666.37M+64.2%	$405.84M-21.3%
Deferred Tax Assets and Other Non-Current Assets	$7.68M+0.8%	$7.62M—	$0—	——
Other non-current assets	$7.68M+0.8%	$7.62M—	$0—	——
Software and Technology Licenses, Net	$7.68M+0.8%	$7.62M—	$0—	——
Accrued expenses and other current liabilities	——	$51.12M—	——	——
Other accrued liabilities	$175K-35.9%	$273K+1,720%	$15K-95.7%	$350K—
Professional Service Fees Payable	——	$789K+69.7%	$465K-18.7%	$572K-15.8%
Common Stock Shares Issued	——	170.1M+16.8%	145.6M+11.7%	130.3M+11.9%
Common Stock Shares Outstanding	——	$88.96M-69.7%	$293.92M+231%	$88.92M+148,098%
Convertible Preferred Stock Authorized Shares	——	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$20K+25.0%	$16K+14.3%	$14K+7.7%	$13K+8.3%
Number of Exercisable Options	——	——	——	——
Preferred Stock Par Value Per Share	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	——	13M-0.5%	13M+11.5%	11.7M+45.7%
Shares Reserved for Future Issuance Under Stock Plans	——	23M+19.7%	19.2M+17.8%	16.3M+213%
Weighted Average Exercise Price of Outstanding Options	——	$12.00+21.8%	$9.85+22.4%	$8.05-5.1%
Accrued bonuses	——	$15.62M+5.9%	$14.74M+95.8%	$7.53M+69.0%
Professional service fees	——	$789K+69.7%	$465K-18.7%	$572K-15.8%
Due to Roivant Sciences Ltd.	——	$273K—	——	——
Research and development expenses	——	$32.62M+32.4%	$24.63M-21.3%	$31.32M+72.1%
Employee severance	——	$263K—	——	——
Common stock, capital shares reserved for future issuance	——	$23.04M+19.7%	$19.25M+17.8%	$16.34M+213%
Common stock, no par value (in dollars per share)	——	$0.000.0%	$0.000.0%	$0.000.0%
Common stock, shares authorized (in shares)	——	$500M0.0%	$500M0.0%	$500M0.0%
Common stock, shares issued (in shares)	——	$170.11M+16.8%	$145.58M+11.7%	$130.33M+11.9%
Common Stock, Shares, Outstanding	——	$170.11M+16.8%	$145.58M+11.7%	$130.33M+11.9%
Preferred stock, shares designated as Series A Junior Participating Preferred Stock (in shares)	——	10K0.0%	10K0.0%	10K0.0%
Cumulative milestone payments	——	——	——	——
Consideration paid	——	——	——	——
Other accrued liabilities	——	$1.55M+5.6%	$1.47M+9.2%	$1.35M-4.7%
Preferred Stock, Par or Stated Value Per Share	——	——	——	——
Preferred Stock, Shares Authorized	——	——	——	——
Prepaid expenses	$42.76M-16.4%	$51.18M+106%	$24.9M-7.5%	$26.92M+330%
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	——	$12.96M-0.5%	$13.03M+11.5%	$11.68M+45.7%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	——	$12+21.8%	$9.85+22.4%	$8.05-5.1%
Incentive stock program, shares reserved for future grants (in shares)	——	$6.03M+188%	$2.09M+254%	$590.32K-73.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	$88.96M-69.7%	$293.92M+231%	$88.92M+148,098%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Immunovant, Inc.'s total assets?: Immunovant, Inc. (IMVT) holds $957.0M in total assets, up 23.3% year over year.
How much debt does Immunovant, Inc. have?: Immunovant, Inc. carries $72.0K in total debt against $852.6M of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Immunovant, Inc. have?: Immunovant, Inc. holds $902.1M in cash and equivalents.
Can Immunovant, Inc. cover its short-term obligations?: Its current ratio is 9.09 — current assets exceed current liabilities.
Where does Immunovant, Inc.'s balance sheet data come from?: Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.